文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

瑞德西韦与标准治疗对中度COVID-19患者第11天临床状态的影响:一项随机临床试验

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2020-01-01

这项随机、开放标签试验纳入584例中度COVID-19住院患者,比较5天或10天瑞德西韦与标准治疗。

要点

  • 5天瑞德西韦组第11天临床状态分布优于标准治疗,但临床意义不确定。
  • 10天瑞德西韦组第11天临床状态与标准治疗无显著差异。
  • 瑞德西韦组恶心、低钾血症和头痛比标准治疗更常见。

核心结论

  • 中度COVID-19患者中,10天瑞德西韦组第11天临床状态与标准治疗无统计学显著差异。
  • 5天瑞德西韦组第11天临床状态与标准治疗有统计学显著差异,但差异的临床重要性不确定。

研究设计与样本

  • 随机、开放标签试验,在美国、欧洲和亚洲105家医院进行,纳入确诊SARS-CoV-2感染且中度COVID-19肺炎的住院患者。
  • 患者按1:1:1随机接受10天瑞德西韦(n=197)、5天瑞德西韦(n=199)或标准治疗(n=200)。
  • 共596例随机,584例开始研究并接受瑞德西韦或继续标准治疗,533例(91%)完成试验。

主要发现

  • 第28天,5天瑞德西韦组死亡2例(1%),10天组死亡3例(2%),标准治疗组死亡4例(2%)。
  • 瑞德西韦组较标准治疗组更常见恶心(10% vs 3%)、低钾血症(6% vs 2%)和头痛(5% vs 3%)。

关键数值与推荐

  • 主要终点为第11天临床状态,采用7点序贯量表(1=死亡,7=出院)。
  • 瑞德西韦静脉给药:第1天200 mg,之后100 mg/d。
  • 5天瑞德西韦组中位治疗时长5天,10天瑞德西韦组中位治疗时长6天。

临床怎么用

  • 对于中度COVID-19住院患者,5天瑞德西韦程可改善第11天临床状态分布,但需权衡临床意义的不确定性。
  • 10天瑞德西韦程未显示优于标准治疗,临床决策时应考虑疗程差异。

局限性

  • 开放标签设计可能引入偏倚。
  • 研究纳入时间为2020年3月至4月,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Remdesivir demonstrated clinical benefit in a placebo-controlled trial in patients with severe coronavirus disease 2019 (COVID-19), but its effect in patients with moderate disease is unknown. OBJECTIVE: To determine the efficacy of 5 or 10 days of remdesivir treatment compared with standard care on clinical status on day 11 after initiation of treatment. DESIGN, SETTING, AND PARTICIPANTS: Randomized, open-label trial of hospitalized patients with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and moderate COVID-19 pneumonia (pulmonary infiltrates and room-air oxygen saturation >94%) enrolled from March 15 through April 18, 2020, at 105 hospitals in the United States, Europe, and Asia. The date of final follow-up was May 20, 2020. INTERVENTIONS: Patients were randomized in a 1:1:1 ratio to receive a 10-day course of remdesivir (n = 197), a 5-day course of remdesivir (n = 199), or standard care (n = 200). Remdesivir was dosed intravenously at 200 mg on day 1 followed by 100 mg/d. MAIN OUTCOMES AND MEASURES: The primary end point was clinical status on day 11 on a 7-point ordinal scale ranging from death (category 1) to discharged (category 7). Differences between remdesivir treatment groups and standard care were calculated using proportional odds models and expressed as odds ratios. An odds ratio greater than 1 indicates difference in clinical status distribution toward category 7 for the remdesivir group vs the standard care group. RESULTS: Among 596 patients who were randomized, 584 began the study and received remdesivir or continued standard care (median age, 57 [interquartile range, 46-66] years; 227 [39%] women; 56% had cardiovascular disease, 42% hypertension, and 40% diabetes), and 533 (91%) completed the trial. Median length of treatment was 5 days for patients in the 5-day remdesivir group and 6 days for patients in the 10-day remdesivir group. On day 11, patients in the 5-day remdesivir group had statistically significantly higher odds of a better clinical status distribution than those receiving standard care (odds ratio, 1.65; 95% CI, 1.09-2.48; P = .02). The clinical status distribution on day 11 between the 10-day remdesivir and standard care groups was not significantly different (P = .18 by Wilcoxon rank sum test). By day 28, 9 patients had died: 2 (1%) in the 5-day remdesivir group, 3 (2%) in the 10-day remdesivir group, and 4 (2%) in the standard care group. Nausea (10% vs 3%), hypokalemia (6% vs 2%), and headache (5% vs 3%) were more frequent among remdesivir-treated patients compared with standard care. CONCLUSIONS AND RELEVANCE: Among patients with moderate COVID-19, those randomized to a 10-day course of remdesivir did not have a statistically significant difference in clinical status compared with standard care at 11 days after initiation of treatment. Patients randomized to a 5-day course of remdesivir had a statistically significant difference in clinical status compared with standard care, but the difference was of uncertain clinical importance. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04292730.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2020. PMID: 32821939. doi:10.1001/jama.2020.16349

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。